Townsend Raymond 4
4 · Kindred Biosciences, Inc. · Filed Mar 19, 2018
Insider Transaction Report
Form 4
Townsend Raymond
Director
Transactions
- Sale
Common Stock
2018-03-15$9.45/sh−1,760$16,632→ 23,297 total - Exercise/Conversion
Stock Option (right to buy)
2018-03-16−910→ 20,470 totalExercise: $3.45Exp: 2026-01-08→ Common Stock (910 underlying) - Exercise/Conversion
Common Stock
2018-03-15$3.45/sh+1,760$6,072→ 25,057 total - Exercise/Conversion
Common Stock
2018-03-16$3.45/sh+1,578$5,444→ 27,928 total - Exercise/Conversion
Common Stock
2018-03-15$3.45/sh+3,053$10,533→ 26,350 total - Exercise/Conversion
Stock Option (right to buy)
2018-03-16−1,578→ 18,892 totalExercise: $3.45Exp: 2026-01-08→ Common Stock (1,578 underlying) - Exercise/Conversion
Common Stock
2018-03-16$3.45/sh+910$3,140→ 27,260 total - Sale
Common Stock
2018-03-16$9.45/sh−910$8,600→ 26,350 total - Exercise/Conversion
Stock Option (right to buy)
2018-03-15−3,053→ 21,380 totalExercise: $3.45Exp: 2026-01-08→ Common Stock (3,053 underlying) - Exercise/Conversion
Stock Option (right to buy)
2018-03-15−1,760→ 24,433 totalExercise: $3.45Exp: 2026-01-08→ Common Stock (1,760 underlying)
Footnotes (2)
- [F1]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2017.
- [F2]The option vested 25% quarterly following January 8, 2016, the date of grant.